LBX(SH:603883)2018-04-19 16:00Financial Performance - Operating revenue rose by 27.90% to CNY 2,210,763,292 year-on-year[5] - Net profit attributable to shareholders increased by 15.19% to CNY 130,543,384 compared to the same period last year[5] - The company reported a significant increase in minority shareholder profit, which rose by 133.82% to RMB 20,182,270[11] - Total operating revenue for the first quarter of 2018 was CNY 512,450,609, an increase of 25.7% compared to CNY 407,499,658 in the same period last year[32] - Operating profit reached CNY 44,133,871, up 55.1% from CNY 28,453,334 year-over-year[33] - The company reported a total profit of CNY 45,687,704, which is a 39.4% increase compared to CNY 32,759,867 in the previous year[33] Cash Flow - Cash flow from operating activities improved by 10.02% to CNY 227,872,561[5] - Cash inflow from operating activities totaled CNY 2,026,002,385, compared to CNY 1,979,972,273 in the previous year, indicating a growth in operational cash flow[36] - Operating cash flow for Q1 2018 was CNY 114,626,054, a decrease of 51% compared to CNY 235,849,742 in the previous period[39] - Total cash inflow from operating activities was CNY 724,073,919, up 9.5% from CNY 661,118,489 year-over-year[39] - The company’s cash flow from operating activities was impacted by increased payments to suppliers and employees, totaling CNY 78,761,851 for employee payments[39] Assets and Liabilities - Total assets increased by 6.57% to CNY 7,138,997,667 compared to the end of the previous year[5] - Non-current assets totaled CNY 3,035,200,511, up from CNY 2,765,972,126, reflecting a growth of 9.7%[26] - Total liabilities amounted to CNY 1,931,274,986, up from CNY 1,899,385,259, representing a growth of 1.7%[27] - Current liabilities rose to CNY 1,137,277,975, compared to CNY 1,105,813,107, indicating an increase of 2.0%[27] - Owner's equity increased to CNY 2,944,111,966 from CNY 2,910,534,879, showing a rise of 1.1%[27] Revenue and Costs - Total operating costs amounted to CNY 2,028,848,815, which is a 28.6% increase from CNY 1,576,078,850 year-over-year[30] - Sales expenses increased to CNY 111,044,940, up 25% from CNY 88,941,083 in the same period last year[32] - The retail segment generated revenue of RMB 1,966,433,203 with a gross margin of 39.16%, up from 21.59% last year[13] - The gross margin for the pharmaceutical manufacturing segment was 29.76%, down from 33.67% last year[13] Shareholder Information - The number of shareholders reached 12,392 at the end of the reporting period[8] - Basic and diluted earnings per share were both CNY 0.46, compared to CNY 0.42 in the same quarter last year[31] Investment Activities - Cash flow from investment activities was negative RMB 274,511,896, an increase of 84.45% compared to the previous period[11] - The company plans to issue convertible bonds totaling up to RMB 400,000,000, pending shareholder approval[17] - New software development expenditures were recorded at CNY 642,483, indicating ongoing investment in technology[10] Inventory and Receivables - The inventory balance increased to RMB 1,553,567,948, up from RMB 1,311,446,521 at the beginning of the year[21] - Accounts receivable increased to CNY 148,046,827 from CNY 120,335,830, reflecting a growth of 22.9%[25] - Inventory levels rose to CNY 207,305,715 from CNY 156,170,767, an increase of 32.7%[26] Cash and Equivalents - The company’s cash and cash equivalents decreased to RMB 1,258,153,212 from RMB 1,354,758,264 at the beginning of the year[21] - Cash and cash equivalents at the end of the period were CNY 650,505,071, down from CNY 832,587,869 at the beginning of the period[40] - The total cash and cash equivalents decreased by CNY 182,082,798 during the quarter, contrasting with an increase of CNY 106,731,088 in the previous period[40]